A detailed history of Livforsakringsbolaget Skandia, Omsesidigt transactions in United Therapeutics Corp stock. As of the latest transaction made, Livforsakringsbolaget Skandia, Omsesidigt holds 28,100 shares of UTHR stock, worth $9.87 Million. This represents 0.54% of its overall portfolio holdings.

Number of Shares
28,100
Previous 400 6925.0%
Holding current value
$9.87 Million
Previous $143,000 6832.87%
% of portfolio
0.54%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 28, 2025

BUY
$348.66 - $410.0 $9.66 Million - $11.4 Million
27,700 Added 6925.0%
28,100 $9.91 Million
Q3 2024

Oct 10, 2024

SELL
$311.04 - $363.55 $6.36 Million - $7.43 Million
-20,450 Reduced 98.08%
400 $143,000
Q2 2024

Jul 15, 2024

BUY
$228.26 - $319.04 $1.05 Million - $1.47 Million
4,600 Added 28.31%
20,850 $6.64 Million
Q3 2023

Oct 20, 2023

BUY
$211.82 - $248.24 $296,548 - $347,536
1,400 Added 9.43%
16,250 $3.67 Million
Q2 2023

Jul 06, 2023

BUY
$205.19 - $232.99 $61,557 - $69,897
300 Added 2.06%
14,850 $3.28 Million
Q1 2023

May 15, 2023

BUY
$212.99 - $276.17 $2.31 Million - $3 Million
10,850 Added 293.24%
14,550 $3.26 Million
Q4 2021

Feb 14, 2022

BUY
$184.32 - $216.08 $129,024 - $151,256
700 Added 23.33%
3,700 $798,000
Q1 2020

Apr 22, 2020

SELL
$79.39 - $115.35 $98,364 - $142,918
-1,239 Reduced 29.23%
3,000 $284,000
Q2 2019

Jul 19, 2019

SELL
$76.06 - $120.81 $30,424 - $48,324
-400 Reduced 8.62%
4,239 $331,000
Q3 2018

Oct 26, 2018

SELL
$113.81 - $129.46 $113,810 - $129,460
-1,000 Reduced 17.73%
4,639 $593,000
Q4 2017

Jan 18, 2018

SELL
$118.58 - $151.28 $23,716 - $30,256
-200 Reduced 3.43%
5,639 $834,000
Q3 2017

Oct 12, 2017

BUY
$114.6 - $136.81 $669,149 - $798,833
5,839
5,839 $685,000

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Livforsakringsbolaget Skandia, Omsesidigt Portfolio

Follow Livforsakringsbolaget Skandia, Omsesidigt and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Livforsakringsbolaget Skandia, Omsesidigt, based on Form 13F filings with the SEC.

News

Stay updated on Livforsakringsbolaget Skandia, Omsesidigt with notifications on news.